• Must have received at least 2 cycles of systemic therapy and
• Who are within 2-12 months of initiation of the initial therapy
• Willing to undergo tandem transplant

CTN-0702 CBCI-207

A Phase III, Multicenter trial of tandem auto transplants plus Lenalidomide Maintenance vs. a Single Auto Transplant plus consolidation with Lenalidomide, bortezomib, and Dex (RVD)
followed by Lenalidomide Maintenance vs.a Single Auto Transplant plus Lenolidomide Maintenance.

• Must have measurable disease - Serum M Protein ≥0.5 g/dL, Urine M-Protein ≥200 mg/24hr, Involved FLC level ≥10 mg/dl or measurable plasmacytoma

* Must have had at least two prior therapies.

Threshold CBCI-240

A Phase 1/2 Open-Label Study to Assess teh Safety, Tolerability and Preliminary Efficacy of TH-302, A Hypoxia-Activated Prodrug, and Dexamethasone with or Without Bortezoib in Subjects with Relapsed/Refractory Multiple Myeloma

• Must have measurable disease - Serum M Protein ≥ 0.5 g/dL or Urine Bence-Jones Protein ≥ 200 mg/24hr
• Cannot have had previous therapy with Pomalidomide
• Must have documented progression as per the IMWG during or after the last treatment

Celgene 009 CBCI-238

A Multicenter, Single- Arm, Open-Label Treatment use Program for Pomalidomide (POM) in Combination with Low Dose Dexamethasone (LD-Dex) in Subjects with Relapsed or Refractory Multiple Myeloma.

• Must have measurable disease - Serum M Protein ≥ 0.5 g/dL or Urine Bence-Jones Protein ≥ 200 mg/24hr
• Cannot have had previous therapy with Pomalidomide
• Must have documented progression as per the IMWG during or after the last treatment

Celgene 008 CBCI-233 

A Phase 1 Multi-Center, Open-Label, Dose-Escalation Study to Determine the Pharmacokinetics and Safety of Pomalidomide When Given in Combination With Low Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma and Impared Renal Function.

• Patients must have measurable serum m-protein of 0.5 mg or quantitative IgA levels of ≥ 1 g/dL Or UPEP of ≥ 200 mg/24 hours, or involved light chains of ≥ 10 mg/dL provided SFLC ratio s abnormal, or measurable plasmacytomas
• Cannot have diabetes
• Cannot have received more than 5 prior lines of therapy

Intellikine CBCI-221
 
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects with Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

• Must have measurable disease - Serum M  Protein ≥ 0.5 g/dL and/or
• Urine Bence-Jones Protein ≥ 200 mg/24hr
• Patients must have documented at least PR to at least 1 line of prior therapy.
• Patient must have received no more than 3 prior treatment regimens.

Onyx-003 CBCI-236

A Randomized, Open-label, Phase 3 Sudy of Carfilzomib Puls Dexamethasone vs. Bortezomib Plus Dexamethasone in Pantients with Relapsed Multiple Myeloma